Voriconazole Test System Classified as Class II by FDA
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying the voriconazole test system as a Class II device with special safety rules, making it safer and easier to get to patients. This change lowers regulatory hurdles, speeding up access to this important medical test without extra costs. The new classification is effective May 9, 2025, benefiting device makers and patients alike.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Voriconazole Test Moved to Class II
The FDA has classified the voriconazole test system as Class II (special controls) effective May 9, 2025 (classification was applicable May 5, 2017). FDA states this classification will reduce regulatory burdens and enhance patients' access to the test by placing it in a lower device class than the automatic Class III assignment.
Enables Use as Predicate for 510(k) Devices
By classifying the device into Class II via the De Novo process, the voriconazole test system can serve as a predicate device that other sponsors may rely on to submit less-burdensome 510(k) premarket notifications rather than De Novo or premarket approval.
Required Validation Studies and Study Details
Manufacturers must meet special controls including design verification and validation with: precision studies using a minimum of three samples at different concentrations (including near medical decision points), method comparison data collected at three laboratory sites with a comparator method not biased by nonspecific detection, interference studies for co-administered medications, and cross-reactivity data for N-oxide voriconazole.
Labeling Must Carry Specific Warning
The device labeling must include the warning statement: "This assay should only be used in conjunction with information available from clinical evaluations and other diagnostic procedures." This labeling requirement is part of the special controls for the voriconazole test system (21 CFR 862.3970(b)(2)).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08147, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Breast Milk Macronutrients Test System
The FDA is officially putting the breast milk macronutrients test system into Class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps companies bring these helpful devices to moms and babies faster and safer. The new rules took effect on May 9, 2025, making it easier and quicker to get these tests to market without extra costs.
Next: 2025-08149, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect Nucleic Acids From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections and Associated Resistance Marker(s)
The FDA is officially classifying devices that detect DNA from non-viral germs causing sexually transmitted infections (STIs) and their resistance markers as Class II, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps companies bring these important tests to patients faster and safer, starting May 9, 2025. Labs, device makers, and patients will all benefit from quicker access to innovative STI testing without extra red tape.